Identification of Maturity-Onset-Diabetes of the Young (MODY) mutations in a country where diabetes is endemic

Hessa Al-Kandari 1 2, Dalia Al-Abdulrazzaq 1 3, Lena Davidsson 1, Rasheeba Nizam 4, Sindhu Jacob 4, Motasem Melhem 4, Sumi Elsa John 4, Fahd Al-Mulla 5

Affiliations

09 August 2021

-

doi: 10.1038/s41598-021-95552-z

Abstract

Genetic variants responsible for Maturity-Onset-Diabetes of the Young (MODY) in Kuwait were investigated. A newly established a National Referral Clinic, the Dasman Diabetes Institute (DDI-NRC), assessed forty-five members from 31 suspected MODY families by whole exome sequencing. Thirty-three of the 45 samples were independently sequenced at the DDI-NRI, Exeter University, UK ( https://www.diabetesgenes.org/ ) using targeted 21-gene panel approach. Pathogenic mutations in GCK, HNF1A, HNF1B, HNF4A, and PDX1 confirmed MODY in 7 families, giving an overall positivity rate of 22.6% in this cohort. Novel variants were identified in three families in PDX1, HNF1B, and HNF1B. In this cohort, Multiplex Ligation-dependent Probe Amplification assay did not add any value to MODY variant detection rate in sequencing negative cases. In highly selected familial autoantibody negative diabetes, known MODY genes represent a minority and 77.3% of the familial cases have yet to have a causal variant described.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1 (A) Represents pedigree of a family positive for Maturity Onset Diabetes of the Young (MODY4). The square symbol represents male, and the circle represents female. The filled in symbols indicate affected individuals and the blue arrow indicates the index case. Next generation sequencing revealed a novel heterozygous missense variant in Pancreatic and duodenal homeobox 1 (PDX1) c.461C > G resulting in p.Thr154Arg. (B) Exome sequencing summary layout depicting part of the PDX1 gene location on chromosome 13 at the top and the exons coverage in green and blue. The location of the variants in exon 2 is represented by a vertical green bar and the reference sequence and the altered codon is highlighted. (C) Chromatogram represents Sanger sequencing results confirming the segregation of heterozygous variants in the mother, the index case and his brother.

Figure 1 (A) Represents pedigree of a family positive for Maturity Onset Diabetes of the Young (MODY4). The square symbol represents male, and the circle represents female. The filled in symbols indicate affected individuals and the blue arrow indicates the index case. Next generation sequencing revealed a novel heterozygous missense variant in Pancreatic and duodenal homeobox 1 (PDX1) c.461C > G resulting in p.Thr154Arg. (B) Exome sequencing summary layout depicting part of the PDX1 gene location on chromosome 13 at the top and the exons coverage in green and blue. The location of the variants in exon 2 is represented by a vertical green bar and the reference sequence and the altered codon is highlighted. (C) Chromatogram represents Sanger sequencing results confirming the segregation of heterozygous variants in the mother, the index case and his brother.

Figure 2 (A) Represents pedigree of a family positive for Maturity Onset Diabetes of the Young (MODY3). The square symbol represents male, and the circle represents female. The filled in symbols indicate affected individuals and the blue arrow indicates the index case. (B) Exome sequencing summary layout depicting part of the HNF1A gene location on chromosome 12 at the top and the exons coverage in green and blue. The location of the c.872dupC, (p.Gly292fs) frameshift mutation is represented by a vertical yellow bar and the reference sequence and the altered codon is highlighted. (C) Chromatogram represents Sanger sequencing of the HNF1A gene in control family member (top) and confirming the heterozygous frameshift mutation in the index (bottom arrow-line).

Figure 2 (A) Represents pedigree of a family positive for Maturity Onset Diabetes of the Young (MODY3). The square symbol represents male, and the circle represents female. The filled in symbols indicate affected individuals and the blue arrow indicates the index case. (B) Exome sequencing summary layout depicting part of the HNF1A gene location on chromosome 12 at the top and the exons coverage in green and blue. The location of the c.872dupC, (p.Gly292fs) frameshift mutation is represented by a vertical yellow bar and the reference sequence and the altered codon is highlighted. (C) Chromatogram represents Sanger sequencing of the HNF1A gene in control family member (top) and confirming the heterozygous frameshift mutation in the index (bottom arrow-line).

Figure 3 (A) Represents pedigree of a family positive for Maturity Onset Diabetes of the Young (MODY3). The square symbol represents male, and the circle represents female. The filled in symbols indicate affected individuals and the blue arrow indicates the index case. Next generation sequencing revealed a novel heterozygous missense variant in HNF1A, c.8C > A, resulting in p.Ser3Tyr. (B) Chromatogram represents Sanger sequencing results confirming the segregation of heterozygous variant in the index case, affected and unaffected family members.

Figure 3 (A) Represents pedigree of a family positive for Maturity Onset Diabetes of the Young (MODY3). The square symbol represents male, and the circle represents female. The filled in symbols indicate affected individuals and the blue arrow indicates the index case. Next generation sequencing revealed a novel heterozygous missense variant in HNF1A, c.8C > A, resulting in p.Ser3Tyr. (B) Chromatogram represents Sanger sequencing results confirming the segregation of heterozygous variant in the index case, affected and unaffected family members.

Similar articles

Frequency and characterization of mutations in genes in a large cohort of patients referred to MODY registry.

Breidbart E, Deng L, Lanzano P, Fan X, Guo J, Leibel RL, LeDuc CA, Chung WK.J Pediatr Endocrinol Metab. 2021 Apr 13;34(5):633-638. doi: 10.1515/jpem-2020-0501. Print 2021 May 26.PMID: 33852230 Free PMC article.

The Mutation Spectrum of Maturity Onset Diabetes of the Young (MODY)-Associated Genes among Western Siberia Patients.

Ivanoshchuk DE, Shakhtshneider EV, Rymar OD, Ovsyannikova AK, Mikhailova SV, Fishman VS, Valeev ES, Orlov PS, Voevoda MI.J Pers Med. 2021 Jan 18;11(1):57. doi: 10.3390/jpm11010057.PMID: 33477506 Free PMC article.

Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus.

Yorifuji T, Fujimaru R, Hosokawa Y, Tamagawa N, Shiozaki M, Aizu K, Jinno K, Maruo Y, Nagasaka H, Tajima T, Kobayashi K, Urakami T.Pediatr Diabetes. 2012 Feb;13(1):26-32. doi: 10.1111/j.1399-5448.2011.00827.x. Epub 2011 Nov 8.PMID: 22060211

Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY).

Tosur M, Philipson LH.J Diabetes Investig. 2022 Sep;13(9):1465-1471. doi: 10.1111/jdi.13860. Epub 2022 Jun 16.PMID: 35638342 Free PMC article. Review.

Maturity onset diabetes of the young: Seek and you will find.

Heuvel-Borsboom H, de Valk HW, Losekoot M, Westerink J.Neth J Med. 2016 Jun;74(5):193-200.PMID: 27323672 Review.

Cited by

A case of maturity-onset diabetes of the young type 4 in Korea.

Park GM, Lee S, Seo JY, Lim KI.Ann Pediatr Endocrinol Metab. 2023 Jun;28(2):149-154. doi: 10.6065/apem.2142188.094. Epub 2022 May 16.PMID: 35592899 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878–1884. doi: 10.2337/dc11-0035. - DOI - PMC - PubMed
  2.  
    1. Oliveira SC, Neves JS, Pérez A, Carvalho D. Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management. Endocrinol. Diabetes Nutr. 2020;67:137–147. doi: 10.1016/j.endinu.2019.07.012. - DOI - PubMed
  3.  
    1. Lambert AP, et al. Identifying hepatic nuclear factor 1alpha mutations in children and young adults with a clinical diagnosis of type 1 diabetes. Diabetes Care. 2003;26:333–337. doi: 10.2337/diacare.26.2.333. - DOI - PubMed
  4.  
    1. Møller AM, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in Caucasian families originally classified as having Type I diabetes. Diabetologia. 1998;41:1528–1531. doi: 10.1007/s001250051101. - DOI - PubMed
  5.  
    1. Awa WL, et al. Reclassification of diabetes type in pediatric patients initially classified as type 2 diabetes mellitus: 15 years follow-up using routine data from the German/Austrian DPV database. Diabetes Res. Clin. Pract. 2011;94:463–467. doi: 10.1016/j.diabres.2011.09.011. - DOI - PubMed
  6.  
    1. Kleinberger JW, et al. Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet. Med. 2018;20:583–590. doi: 10.1038/gim.2017.150. - DOI - PMC - PubMed
  7.  
    1. Stanik J, et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia. 2014;57:480–484. doi: 10.1007/s00125-013-3119-2. - DOI - PubMed
  8.  
    1. De Franco E, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: An international cohort study. Lancet. 2015;386:957–963. doi: 10.1016/s0140-6736(15)60098-8. - DOI - PMC - PubMed
  9.  
    1. Hattersley AT, et al. ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes. 2018;19(Suppl 27):47–63. doi: 10.1111/pedi.12772. - DOI - PubMed
  10.  
    1. Pearson ER, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362:1275–1281. doi: 10.1016/s0140-6736(03)14571-0. - DOI - PubMed
  11.  
    1. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60:769–777. doi: 10.1007/s00125-017-4226-2. - DOI - PMC - PubMed
  12.  
    1. Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: Recognition and treatment options. Curr. Diab. Rep. 2018;18:58. doi: 10.1007/s11892-018-1024-2. - DOI - PMC - PubMed
  13.  
    1. Landrum MJ, Kattman BL. ClinVar at five years: Delivering on the promise. Hum. Mutat. 2018;39:1623–1630. doi: 10.1002/humu.23641. - DOI - PubMed
  14.  
    1. Johansson BB, et al. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2017;60:625–635. doi: 10.1007/s00125-016-4167-1. - DOI - PubMed
  15.  
    1. Bellanné-Chantelot C, et al. Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes. 2005;54:3126–3132. doi: 10.2337/diabetes.54.11.3126. - DOI - PubMed
  16.  
    1. Al-Kandari H, Al-Abdulrazzaq D, Davidsson L, Al-Mulla F. Maturity-onset diabetes of the young (MODY): A time to act. Lancet Diabetes Endocrinol. 2020;8:565–566. doi: 10.1016/s2213-8587(20)30150-9. - DOI - PubMed
  17.  
    1. Amara A, et al. Familial early-onset diabetes is not a typical MODY in several Tunisian patients. Tunis Med. 2012;90:882–887. - PubMed
  18.  
    1. Ben Khelifa S, et al. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations. Gene. 2018;651:44–48. doi: 10.1016/j.gene.2018.01.081. - DOI - PubMed
  19.  
    1. Dallali H, et al. Genetic characterization of suspected MODY patients in Tunisia by targeted next-generation sequencing. Acta Diabetol. 2019;56:515–523. doi: 10.1007/s00592-018-01283-5. - DOI - PubMed
  20.  
    1. Woodhouse NJ, et al. Clinically-Defined Maturity Onset Diabetes of the Young in Omanis: Absence of the common Caucasian gene mutations. Sultan Qaboos Univ. Med. J. 2010;10:80–83. - PMC - PubMed
  21.  
    1. Hebbar P, et al. Genome-wide association study identifies novel risk variants from RPS6KA1, CADPS, VARS, and DHX58 for fasting plasma glucose in Arab population. Sci. Rep. 2020;10:152. doi: 10.1038/s41598-019-57072-9. - DOI - PMC - PubMed
  22.  
    1. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl450, 76-85, 10.1111/j.1651-2227.2006.tb02378.x (2006) - PubMed
  23.  
    1. Fattahi Z, et al. Iranome: A catalog of genomic variations in the Iranian population. Hum. Mutat. 2019;40:1968–1984. doi: 10.1002/humu.23880. - DOI - PubMed
  24.  
    1. Doddabelavangala Mruthyunjaya M, et al. Comprehensive maturity onset diabetes of the Young (MODY) gene screening in pregnant women with Diabetes in India. PLoS ONE. 2017;12:e0168656. doi: 10.1371/journal.pone.0168656. - DOI - PMC - PubMed
  25.  
    1. Hildebrand JM, et al. A family harboring an MLKL loss of function variant implicates impaired necroptosis in diabetes. Cell Death Dis. 2021;12:345. doi: 10.1038/s41419-021-03636-5. - DOI - PMC - PubMed
  26.  
    1. Wright NM, Metzger DL, Borowitz SM, Clarke WL. Permanent neonatal diabetes mellitus and pancreatic exocrine insufficiency resulting from congenital pancreatic agenesis. Am. J. Dis. Child. 1993;147:607–609. doi: 10.1001/archpedi.1993.02160300013005. - DOI - PubMed
  27.  
    1. Ellard S. Hepatocyte nuclear factor 1 alpha (HNF-1 alpha) mutations in maturity-onset diabetes of the young. Hum. Mutat. 2000;16:377–385. doi: 10.1002/1098-1004(200011)16:5<377::aid-humu1>3.0.co;2-2. - DOI - PubMed
  28.  
    1. Paradiso V, et al. Diagnostic targeted sequencing panel for hepatocellular carcinoma genomic screening. J. Mol. Diagn. 2018;20:836–848. doi: 10.1016/j.jmoldx.2018.07.003. - DOI - PubMed
  29.  
    1. Codner E, et al. Glucokinase mutations in young children with hyperglycemia. Diabetes Metab. Res. Rev. 2006;22:348–355. doi: 10.1002/dmrr.622. - DOI - PubMed
  30.  
    1. Massa O, et al. High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetologia. 2001;44:898–905. doi: 10.1007/s001250100530. - DOI - PubMed
  31.  
    1. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5–9 September 2004. Diabetologia47, A1-a464, 10.1007/bf03375463 (2004). - PMC - PubMed
  32.  
    1. Shaltout AA, et al. Further evidence for the rising incidence of childhood Type 1 diabetes in Kuwait. Diabet. Med. 2002;19:522–525. doi: 10.1046/j.1464-5491.2002.00703.x. - DOI - PubMed
  33.  
    1. Shaltout AA, et al. High incidence of childhood-onset IDDM in Kuwait. Kuwait Study Group of Diabetes in Childhood. Diabetes Care. 1995;18:923–927. doi: 10.2337/diacare.18.7.923. - DOI - PubMed
  34.  
    1. Bener A, Yousafzai MT, Al-Hamaq AO, Mohammad AG, Defronzo RA. Parental transmission of type 2 diabetes mellitus in a highly endogamous population. World J. Diabetes. 2013;4:40–46. doi: 10.4239/wjd.v4.i2.40. - DOI - PMC - PubMed
  35.  
    1. Cheţa D, et al. A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabete Metab. 1990;16:11–15. - PubMed
  36.  
    1. Alhyas L, McKay A, Majeed A. Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: A systematic review. PLoS ONE. 2012;7:e40948. doi: 10.1371/journal.pone.0040948. - DOI - PMC - PubMed
  37.  
    1. Elkum N, Al-Arouj M, Sharifi M, Shaltout A, Bennakhi A. Prevalence of childhood obesity in the state of Kuwait. Pediatr. Obes. 2016;11:e30–e34. doi: 10.1111/ijpo.12090. - DOI - PubMed
  38.  
    1. Małachowska B, et al. Monogenic diabetes prevalence among Polish children-Summary of 11 years-long nationwide genetic screening program. Pediatr. Diabetes. 2018;19:53–58. doi: 10.1111/pedi.12532. - DOI - PubMed
  39.  
    1. Schober E, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: Experience from a large multicentre database. Diabet. Med. 2009;26:466–473. doi: 10.1111/j.1464-5491.2009.02720.x. - DOI - PubMed
  40.  
    1. Shields BM, et al. Maturity-onset diabetes of the young (MODY): How many cases are we missing? Diabetologia. 2010;53:2504–2508. doi: 10.1007/s00125-010-1799-4. - DOI - PubMed
  41.  
    1. Carmody D, et al. GCK-MODY in the US National Monogenic Diabetes Registry: Frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016;53:703–708. doi: 10.1007/s00592-016-0859-8. - DOI - PMC - PubMed
  42.  
    1. Steele AM, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311:279–286. doi: 10.1001/jama.2013.283980. - DOI - PubMed
  43.  
    1. Chakera AJ, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care. 2015;38:1383–1392. doi: 10.2337/dc14-2769. - DOI - PubMed
  44.  
    1. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2008;4:200–213. doi: 10.1038/ncpendmet0778. - DOI - PubMed
  45.  
    1. Stride A, et al. Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1alpha gene mutation carriers. Diabetes Care. 2002;25:2287–2291. doi: 10.2337/diacare.25.12.2287. - DOI - PubMed
  46.  
    1. Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J. Med. Genet. 2006;43:84–90. doi: 10.1136/jmg.2005.032854. - DOI - PMC - PubMed
  47.  
    1. Raile K, et al. Expanded clinical spectrum in hepatocyte nuclear factor 1b-maturity-onset diabetes of the young. J. Clin. Endocrinol. Metab. 2009;94:2658–2664. doi: 10.1210/jc.2008-2189. - DOI - PubMed
  48.  
    1. Amendola LM, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. Am. J. Hum. Genet. 2016;98:1067–1076. doi: 10.1016/j.ajhg.2016.03.024. - DOI - PMC - PubMed

Page Navigation